Currently enrolling patients in a Phase 2 clinical trial
A Phase 2 clinical trial of VPI-2960B for the treatment of diabetic nephropathy is currently enrolling patients with Type 1 and Type 2 diabetes. The 48-week double-blind study is designed to evaluate VPI-2690B compared to placebo in reducing urinary albumin/creatinine ratio (primary endpoint) and improving Estimated Glomerular Filtration Rate (eGFR) levels, both key measures of kidney function.
The study will enroll 300 patients across two cohorts to assess two doses of VPI-2690B (6mg and 18mg) administered subcutaneously by injection twice per month. Vascular Pharmaceuticals is planning an interim analysis from the first cohort in the second half 2015.
For more information on study enrollment, including the clinical protocol and qualification information, please visit ClinicalTrials.gov.